Heart Failure Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Heart Failure Treatment Landscape @ https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight

Key Takeaways from the Heart Failure Pipeline Report

• On February 18, 2026- Boehringer Ingelheim announced a study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure.
• On February 13, 2026- Novo Nordisk A/S conducted a Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
• On February 10, 2026- Help Therapeutics initiated a clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
• DelveInsight's Heart Failure pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Heart Failure treatment.
• The Heart Failure Companies such as Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.
• Promising Heart Failure Pipeline Therapies such as Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin and others.

Stay informed about the cutting-edge advancements in Heart Failure treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Heart Failure Clinical Trials Assessment

The Heart Failure Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Heart Failure Pipeline Report also highlights the unmet needs with respect to the Heart Failure.

Heart Failure Overview

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations.

Heart Failure Emerging Drugs Profile

• Rexlemestrocel-L: Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Enrollment of 566 patients has been completed in a placebo-controlled Phase III trial to evaluate a single dose of Revascor in Class II/III CHF patients across multiple sites in North America. Patients with advanced heart failure constitute the majority of the patients enrolled in this clinical trial program. Currently, the drug is in Phase III stage of its development for the treatment of heart failure.

• HU 6: Rivus Pharmaceuticals

HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body. Currently, the drug is in Phase II stage of its development for the treatment of heart failure.

• HS-001: Heartseed Inc

HS-001, is allogeneic iPSC-derived, highly purified ventricular cardio myocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for the administration of the spheroids into the myocardial layer of the heart. The expected mechanism of action is that the transplanted cardio myocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularisation, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization). In June 2021, Heartseed and Novo Nordisk entered into global collaboration and license agreement for stem cell-based therapy for heart failure. Currently, the drug is in Phase I/II stage of its development for the treatment of heart failure.

• Ribonucleotide reductase based gene therapy: StemCardia

Ribonucleotide reductase based gene therapy is a novel investigational product candidate being developed by StemCardia. The drug candidate is based on Gene transference and Ribonucleotide reductase modulators mechanism of action. Currently, the drug is in preclinical stage of its development for the treatment of heart failure.

Learn more about Heart Failure Drugs opportunities in our groundbreaking Heart Failure research and development projects @ Heart Failure Unmet Needs

The Heart Failure Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
• Heart Failure Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.

Heart Failure Companies

Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Heart Failure Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of Cardiovascular Diseases @ Heart Failure Market Drivers and Barriers, and Future Perspectives

Scope of the Heart Failure Pipeline Report

• Coverage- Global
• Heart Failure Companies- Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.
• Heart Failure Pipeline Therapies- Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin and others.
• Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Heart Failure Pipeline on our website @ Heart Failure Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Heart Failure: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Heart Failure – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rexlemestrocel-L: Mesoblast
9. Mid Stage Products (Phase II)
10. HU 6: Rivus Pharmaceuticals
11. Early Stage Products (Phase I/II)
12. HS-001: Heartseed Inc
13. Preclinical and Discovery Stage Products
14. Ribonucleotide reductase-based gene therapy: StemCardia
15. Inactive Products
16. Heart Failure Key Companies
17. Heart Failure Key Products
18. Heart Failure - Unmet Needs
19. Heart Failure - Market Drivers and Barriers
20. Heart Failure - Future Perspectives and Conclusion
21. Heart Failure Analyst Views
22. Heart Failure Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/heart-failure-pipeline-insight

Oral Mucositis Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Oral Mucositis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oral Mucositis pipeline landscape. It covers the Oral Mucositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Oral Mucositis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Oral Mucositis Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/oral-mucositis-pipeline-insight

Key Takeaways from the Oral Mucositis Pipeline Report

• In January 2026, Emory University announced a study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over multiple time points.
• In December 2025, Tulane University initiated a study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine. This study is funded by Merck & Co., the developers of ERVEBO®. This investigational medicinal product (IMP) was successful in Sierra Leone through the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE), working with the College of Medical and Allied Health Services (COMAHS) at the University of Sierra Leone.
• DelveInsight’s Oral Mucositis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Oral Mucositis treatment.
• The leading Oral Mucositis Companies such as Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics and others.
• Promising Oral Mucositis Therapies such as RRx-001, Dentoxol, GC4419 90mg, Melatonin oral gel 3%, Celecoxib, IZN-6N4, SGX942 and others.

Want to know which companies are leading innovation in Oral Mucositis? Dive into the full pipeline insights @ Oral Mucositis Clinical Trials Assessment

The Oral Mucositis Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Oral Mucositis Pipeline Report also highlights the unmet needs with respect to the Oral Mucositis.

Oral Mucositis Overview

Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation.

Oral Mucositis Emerging Drugs

• GC4419: Galera Therapeutics

GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

• SGX942: Soligenix

SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician’s office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company’s pivotal Phase 3 clinical study (“DOM-INNATE”) for oral mucositis in head and neck cancer patients has completed enrollment.

If you’re tracking ongoing Oral Mucositis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Oral Mucositis Treatment Drugs

The Oral Mucositis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Oral Mucositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oral Mucositis Treatment.
• Oral Mucositis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oral Mucositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oral Mucositis market.

Oral Mucositis Companies

Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics and others.

Oral Mucositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Oral Mucositis Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

From emerging drug candidates to competitive intelligence, the Oral Mucositis Pipeline Report covers it all – check it out now @ Oral Mucositis Market Drivers and Barriers, and Future Perspectives

Scope of the Oral Mucositis Pipeline Report

• Coverage- Global
• Oral Mucositis Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics and others.
• Oral Mucositis Therapies- RRx-001, Dentoxol, GC4419 90mg, Melatonin oral gel 3%, Celecoxib, IZN-6N4, SGX942 and others.
• Oral Mucositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Oral Mucositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Oral Mucositis treatment landscape in this detailed analysis @ Oral Mucositis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Oral Mucositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oral Mucositis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SGX942: Soligenix
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MIT-001: MitoImmune Therapeutics
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Oral Mucositis Key Companies
15. Oral Mucositis Key Products
16. Oral Mucositis- Unmet Needs
17. Oral Mucositis- Market Drivers and Barriers
18. Oral Mucositis- Future Perspectives and Conclusion
19. Oral Mucositis Analyst Views
20. Oral Mucositis Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Soft Tissue Sarcoma Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Soft Tissue Sarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight

Key Takeaways from the Soft Tissue Sarcoma Marketed and Pipeline Drugs Report

• On February 18, 2026- Takara Bio Inc. initiated a study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
• On February 17, 2026- QBiotics Group Limited announced a phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.
• On February 11, 2026- Memorial Sloan Kettering Cancer Center conducted a study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).
• DelveInsight’s Soft Tissue Sarcoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Soft Tissue Sarcoma treatment.
• The leading Soft Tissue Sarcoma Companies such as Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
• Promising Soft Tissue Sarcoma Pipeline Therapies such as Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Soft Tissue Sarcoma Treatment Drugs

Soft Tissue Sarcoma Emerging Drugs Profile

• Fibronum + Doxorubicin: Philogen S.p.A.

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma.

• Chiauranib: Chipscreen Biosciences, Ltd

Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.Currently, the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma.

• LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited

Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma.

The Soft Tissue Sarcoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
• Soft Tissue Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market

Explore groundbreaking therapies and clinical trials in the Soft Tissue Sarcoma Pipeline. Access DelveInsight's detailed report now! @ New Soft Tissue Sarcoma Drugs

Soft Tissue Sarcoma Companies

Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn about new Soft Tissue Sarcoma Marketed and Drug Developments, and key companies with DelveInsight's expert analysis @ Soft Tissue Sarcoma Market Drivers and Barriers

Scope of the Soft Tissue Sarcoma Pipeline Report

• Coverage- Global
• Soft Tissue Sarcoma Companies- Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
• Soft Tissue Sarcoma Pipeline Therapies- Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
• Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Soft Tissue Sarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Soft Tissue Sarcoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Soft Tissue Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Fibronum + Doxorubicin: Philogen S.p.A.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Chiauranib: Chipscreen Biosciences, Ltd
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Drug Name: Company Name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Soft Tissue Sarcoma Key Companies
24. Soft Tissue Sarcoma Key Products
25. Soft Tissue Sarcoma- Unmet Needs
26. Soft Tissue Sarcoma- Market Drivers and Barriers
27. Soft Tissue Sarcoma- Future Perspectives and Conclusion
28. Soft Tissue Sarcoma Analyst Views
29. Soft Tissue Sarcoma Key Companies
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight

Charcot Marie Tooth Clinical Trial Pipeline Accelerates as 10+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Charcot Marie Tooth Disease Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Charcot Marie Tooth therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Charcot Marie Tooth Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-pipeline-insight

Key Takeaways from the Charcot Marie Tooth Pipeline Report

• On February 03, 2026- Novartis Pharmaceuticals announced a study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants. The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
• DelveInsight’s Charcot Marie Tooth Pipeline report depicts a robust space with 10+ active players working to develop 15+ pipeline therapies for Charcot Marie Tooth treatment.
• The leading Charcot Marie Tooth Companies such as Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals, and others.
• Promising Charcot Marie Tooth Therapies such as PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD®) and others.

Want to know which companies are leading innovation in Charcot Marie Tooth? Dive into the full pipeline insights @ Charcot Marie Tooth Clinical Trials Assessment

Charcot Marie Tooth Overview

Charcot-Marie-Tooth disease (CMT) is a group of inherited neurological disorders that affect the peripheral nerves, which are responsible for movement and sensation in the limbs. Named after the three physicians who first described it in 1886, CMT is also known as hereditary motor and sensory neuropathy (HMSN). It is one of the most common inherited neurological disorders, affecting about 1 in 2,500 people. CMT is characterized by progressive muscle weakness and atrophy, primarily in the legs and feet, and, in later stages, in the hands and arms.

Charcot Marie Tooth Disease Emerging Drugs

• PXT3003: Pharnext SA

PXT3003, is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice a day. The three individual components of PXT3003 were selected to downregulate the overexpression of PMP22 protein, leading to improvement of neuronal signaling in dysfunctional peripheral nerves that are an essential part of the pathophysiology of this disease. PXT3003 could also have a positive effect on other cellular types of the motor unit such as the axon (direct protection), neuromuscular junctions or muscle cells. It is currently in Phase III stage of development for the treatment of Charcot Marie tooth disease type 1A.

• IFB-088: InFlectis BioScience

IFB-088 is an orally available small molecule capable of crossing the blood-brain barrier, a cell layer that protects the brain from disease-causing agents and toxins that may be present in the blood. IFB-088 also serves as an inhibitor of certain glutamate receptors. These receptors are involved in a process called excitotoxicity, in which neurons are over-stimulated and fire much more than needed, leading to nerve damage. IFB 088 has the potential to treat several demyelinating subtypes including CMT 1A, CMT 1B and CMT 1E, which affects 150,000 people in the U.S. and Europe. The Company is now planning a Phase II clinical trial in the United States and Europe. The drug is currently in Phase II stage of development for the treatment of Charcot Marie tooth disease.

If you’re tracking ongoing Charcot Marie Tooth Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Charcot Marie Tooth Treatment Drugs

Charcot Marie Tooth Companies

Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals, and others.

The Charcot Marie Tooth Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Charcot Marie Tooth with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Charcot Marie Tooth Treatment.
• Charcot Marie Tooth Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Charcot Marie Tooth Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Charcot Marie Tooth market.

Charcot Marie Tooth Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Charcot Marie Tooth Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Charcot Marie Tooth Pipeline Report covers it all – check it out now @ Charcot Marie Tooth Market Drivers and Barriers, and Future Perspectives

Scope of the Charcot Marie Tooth Pipeline Report

• Coverage- Global
• Charcot Marie Tooth Companies- Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals, and others.
• Charcot Marie Tooth Therapies- PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD®) and others.
• Charcot Marie Tooth Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Charcot Marie Tooth Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Charcot Marie Tooth Treatment landscape in this detailed analysis @ Charcot Marie Tooth Emerging Drugs and Major Players

Table of Content

1. Introduction
2. Executive Summary
3. Charcot Marie Tooth Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Charcot Marie Tooth Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. PXT3003: Pharnext SA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IFB-088: InFlectis BioScience
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Charcot Marie Tooth Disease Key Companies
21. Charcot Marie Tooth Disease Key Products
22. Charcot Marie Tooth Disease- Unmet Needs
23. Charcot Marie Tooth Disease- Market Drivers and Barriers
24. Charcot Marie Tooth Disease- Future Perspectives and Conclusion
25. Charcot Marie Tooth Disease Analyst Views
26. Charcot Marie Tooth Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-pipeline-insight

Metastatic Colorectal Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 150+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this space.

Download DelveInsight’s comprehensive Metastatic Colorectal Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

• On February 12, 2026- Amgen conducted a Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation.
• On February 11, 2026- Shanghai EpimAb Biotherapeutics Co. Ltd. initiated a study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.
• On February 04, 2026- Pfizer announced a phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated braf v600e-mutant, msi h/dmmr metastatic colorectal cancer.
• DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Metastatic Colorectal Cancer treatment.
• The leading Metastatic Colorectal Cancer Companies such as Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
• Promising Metastatic Colorectal Cancer Therapies such as Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.

Discover how the Metastatic Colorectal Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Colorectal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Colorectal Cancer Clinical Trials and Studies

Metastatic Colorectal Cancer Overview

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.

Metastatic Colorectal Cancer Emerging Drugs Profile

• HLX10 (Serplulimab) + HLX04: Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. HLX04 is a bevacizumab biosimilar developed by Henlius independently in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative), which can be used in the treatment of advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). HLX04 can block the interaction between vascular endothelial growth factor (VEGF) and its receptors by binding with VEGF specifically, which then inhibits tumour angiogenesis and thus suppressing the growth and metastases of tumours.

• Lenvatinib: Eisai Inc.

LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below. Currently the drug is in Phase III stage of its development for the treatment of metastatic colorectal cancer.

• PEPI1018: Treos Bio

PolyPEPI-1018, Treos’ lead product candidate, is an off-the-shelf immunotherapy in clinical development for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic. The therapy is in development as a first-line maintenance therapy and as a third-line treatment. The companion diagnostic uses Treos’ proprietary PASCal computational tool to identify Personal EPItopes (PEPIs) that are likely to induce antigen-specific T Cell responses in a patient. In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. PolyPEPI1018 was designed to induce polyvalent T cell responses in a large subpopulation of CRC patients using its PEPI TestTM platform which identifies Personal EPItopes (PEPIs) that are likely to induce antigen-specific T cell responses in a subject. Currently the drug is in Phase II stage of its development for the treatment of metastatic colorectal cancer.

• AUM-001: AUM Biosciences

AUM001 is a highly selective translation inhibitor. It selectively inhibits MNK 1/2 and thereby blocks phosphorylation of eIF4E. This, in turn, interferes with CAP mediated RNA translation, thereby impairing growth signals involved in cancer development, progression, and resistance to therapies. MNK is important in tumor microenvironment (TME) regulation, shifting the balance towards tumor inhibition. Moreover, inhibition of MNK kinases decreases the production of the pro-inflammatory cytokines like TNFα and IL-6, suggesting that MNK kinases and their substrates (eIF4E, hnRNP A1, Spry1/2) play a pivotal role in regulating the innate and adaptive immune compartment. This has the potential to turn “cold” tumors “hot”, increasing the proportion of tumors susceptible to immunotherapies. AUM001 demonstrated encouraging safety, tolerability and target engagement as a monotherapy in two Phase I clinical trials. The global Phase II trial is being conducted in collaboration with MSD, a tradename of Merck & Co., Inc., pursuant to a clinical trial collaboration and supply agreement for KEYTRUDA. Currently, the drug is in the Phase II stage of its development for the treatment of metastatic Colorectal Cancer.

• DKN-01: Leap Therapeutics, Inc.

Sirexatamab (DKN-01) is an investigational humanized IgG4-kappa monoclonal antibody that targets Dickkopf-related protein 1 (DKK1), a modulator of the Wnt signaling pathway. Overexpression of DKK1 has been associated with tumor progression and poor prognosis in various cancers, including colorectal cancer (CRC). In preclinical studies, DKK1 has been identified as a resistance mechanism to commonly used chemotherapy in colorectal cancer models. By binding to and neutralizing DKK1, sirexatamab aims to restore normal Wnt signaling, thereby inhibiting tumor growth and potentially enhancing the efficacy of other anticancer therapies. Currently the drug is in Phase II stage of its development for the treatment of Metastatic Colorectal cancer.

• RO7122290: Hoffmann-La Roche

RO7122290is a novel 4-1BB agonist that targets fibroblast activation protein-a (FAP), which is abundantly expressed by cancer-associated fibroblasts in many tumors. Simultaneous binding of FAP and 4-1BB results in clustering and activation of T- and natural killer cells at the tumor site and simultaneous antitumor activity, which has been demonstrated in preclinical models. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors. The drug is currently in Phase I/II stage of its development for the treatment of metastatic colorectal cancer.

• E7386: Eisai

E7386 is a CBP / β-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and β-catenin, and regulates the Wnt signaling-dependent gene expression. Since E7386 acts on the CBP / β-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand-dependent activation but also activation caused by gene mutations in Wnt signaling factors such as adenomatous polyposis coli (APC) and β-catenin. E7386 is an orally active selective inhibitor of the interaction between β-catenin and CREB binding protein, which is part of the Wnt/β-catenin signaling pathway, disrupts the Wnt/β-catenin signaling pathway in HEK293 and adenomatous polyposis coli (APC)-mutated human gastric cancer ECC10 cells. In preclinical models, E7386 has demonstrated antitumor activity against mouse mammary tumors developed in Mouse Mammary Tumor Virus (MMTV)-Wnt1 transgenic mice. Currently, the drug is in the Phase I/II stage of its development for the treatment of Metastatic Colorectal Cancer.

The Metastatic Colorectal Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
• Metastatic Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Colorectal Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Colorectal Cancer Unmet Needs

Metastatic Colorectal Cancer Companies

Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Colorectal Cancer Therapies and key Metastatic Colorectal Cancer Developments @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Colorectal Cancer Pipeline Report

• Coverage- Global
• Metastatic Colorectal Cancer Companies-Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
• Metastatic Colorectal Cancer Therapies- Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
• Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Colorectal Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Colorectal Cancer Pipeline Report—access it now! @ Metastatic Colorectal Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Metastatic colorectal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic colorectal cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Lumakras (sotorasib): Amgen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Axitinib: Pfizer
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. NX 1607: Nurix Therapeutics Inc
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Metastatic colorectal cancer Key Companies
23. Metastatic colorectal cancer Key Products
24. Metastatic colorectal cancer- Unmet Needs
25. Metastatic colorectal cancer- Market Drivers and Barriers
26. Metastatic colorectal cancer- Future Perspectives and Conclusion
27. Metastatic Colorectal Cancer Analyst Views
28. Metastatic Colorectal Cancer Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight

Oncolytic Virus Cancer Therapy Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report

• In December 2025, Replimune Inc. initiated a Phase 2, open-label, multicenter study evaluating RP2 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab and RP2 monotherapy as second-line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC (Cohort 3).
• In November 2025, Genelux Corporation conducted a OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
• In November 2025, TILT Biotherapeutics Ltd. announced a phase 1/1b clinical trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
• DelveInsight’s Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
• The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
• Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.

Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment

The Oncolytic Virus Cancer Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Oncolytic Virus Cancer Therapy Pipeline Report also highlights the unmet needs with respect to the development of Oncolytic Virus Cancer Therapy.

Oncolytic Virus Cancer Therapy Overview

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

Oncolytic Virus Cancer Therapy Emerging Drugs Profile

• Olvi-Vec: Genelux Corporation

Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

• CAN-2409: Candel Therapeutics

CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.

• CG0070: CG Oncology

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.

• Pelareorep: Oncolytics Biotech

Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.

• ParvOryx: Oryx GmbH

ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.

• SND005: Jiangsu Sinorda Biomedicine

SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.

• VCN-01: VCN Biosciences

VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.

Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs

The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
• Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.

Oncolytic Virus Cancer Therapy Companies

Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intranasal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular

Oncolytic Virus Cancer Therapy Products have been categorized under various molecular types such as

• Oncolytic Virus

Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the Oncolytic Virus Cancer Therapy Pipeline Report

• Coverage- Global
• Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
• Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
• Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website, @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Oncolytic Virus Cancer Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oncolytic Virus Cancer Therapy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Olvi-Vec: Genelux Corporation
9. Mid Stage Products (Phase II)
10. SND005: Jiangsu Sinorda Biomedicine
11. Early Stage Products (Phase I/II)
12. AloCelyvir: Orgenesis
13. Early Stage Products (Phase I)
14. VCN-01: VCN Biosciences
15. Preclinical and Discovery Stage Products
16. SynOV 1.3: Beijing Syngentech
17. Inactive Products
18. Oncolytic Virus Cancer Therapy Key Companies
19. Oncolytic Virus Cancer Therapy Key Products
20. Oncolytic Virus Cancer Therapy- Unmet Needs
21. Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
22. Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
23. Oncolytic Virus Cancer Therapy Analyst Views
24. Oncolytic Virus Cancer Therapy Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021